Kopran (KOPRAN) Stock Overview
An integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
KOPRAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kopran Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹132.85 |
| 52 Week High | ₹235.90 |
| 52 Week Low | ₹131.10 |
| Beta | 0.39 |
| 1 Month Change | -20.56% |
| 3 Month Change | -17.46% |
| 1 Year Change | -36.10% |
| 3 Year Change | -18.57% |
| 5 Year Change | 13.94% |
| Change since IPO | 58.15% |
Recent News & Updates
Recent updates
Is Kopran (NSE:KOPRAN) A Risky Investment?
Sep 09
Kopran (NSE:KOPRAN) Has Announced A Dividend Of ₹3.00
Aug 14Kopran Limited's (NSE:KOPRAN) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
Apr 17Kopran Limited (NSE:KOPRAN) Surges 30% Yet Its Low P/E Is No Reason For Excitement
Apr 17Does Kopran (NSE:KOPRAN) Have A Healthy Balance Sheet?
Jan 29The Market Doesn't Like What It Sees From Kopran Limited's (NSE:KOPRAN) Earnings Yet As Shares Tumble 29%
Nov 18Kopran Limited's (NSE:KOPRAN) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 14Kopran (NSE:KOPRAN) Has Announced A Dividend Of ₹3.00
Aug 20Insufficient Growth At Kopran Limited (NSE:KOPRAN) Hampers Share Price
Jul 31Does Kopran (NSE:KOPRAN) Have A Healthy Balance Sheet?
Jun 12Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jan 05Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jun 03Kopran's (NSE:KOPRAN) Dividend Will Be Increased To ₹3.00
Jul 14Here's Why I Think Kopran (NSE:KOPRAN) Might Deserve Your Attention Today
Nov 25Should You Be Adding Kopran (NSE:KOPRAN) To Your Watchlist Today?
Jun 10These 4 Measures Indicate That Kopran (NSE:KOPRAN) Is Using Debt Safely
Mar 21If You Had Bought Kopran (NSE:KOPRAN) Stock A Year Ago, You Could Pocket A 327% Gain Today
Feb 14Kopran Limited's (NSE:KOPRAN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 24Is Kopran (NSE:KOPRAN) A Risky Investment?
Dec 20
Shareholder Returns
| KOPRAN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -11.9% | 0.2% | 0.09% |
| 1Y | -36.1% | -0.2% | 5.4% |
Return vs Industry: KOPRAN underperformed the Indian Pharmaceuticals industry which returned -0.3% over the past year.
Return vs Market: KOPRAN underperformed the Indian Market which returned 5.2% over the past year.
Price Volatility
| KOPRAN volatility | |
|---|---|
| KOPRAN Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: KOPRAN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: KOPRAN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 1,024 | Surendra Somani | www.kopran.com |
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular.
Kopran Limited Fundamentals Summary
| KOPRAN fundamental statistics | |
|---|---|
| Market cap | ₹6.42b |
| Earnings (TTM) | ₹175.99m |
| Revenue (TTM) | ₹5.92b |
Is KOPRAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KOPRAN income statement (TTM) | |
|---|---|
| Revenue | ₹5.92b |
| Cost of Revenue | ₹3.87b |
| Gross Profit | ₹2.05b |
| Other Expenses | ₹1.87b |
| Earnings | ₹175.99m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.64 |
| Gross Margin | 34.62% |
| Net Profit Margin | 2.97% |
| Debt/Equity Ratio | 31.3% |
How did KOPRAN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 07:17 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kopran Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Harini V. | FirstCall Research |